- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05881681
A Mindfulness Approach to UA for Afro-descendants
March 13, 2024 updated by: Brown University
A Mindfulness Approach to Unwinding Anxiety for Afro-descendants
The goal of this clinical trial is to test an app-based mindfulness training program in an Afro-descendant population. The main question[s] it aims to answer are:
- What changes, if any, does the app need?
- Is it effective in reducing anxiety among this population?
Participants will be asked to:
- Use an app-based mindfulness training program daily
- Complete online surveys at baseline and 2 months post-treatment initiation
- Complete focused interviews via Zoom at baseline and 2 months post-treatment initiation
- Complete daily voice diaries via Zoom
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
15
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15215
- University of Pittsburgh Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- GAD-7 ≥ 10
- Self-identify as Black American and/or Afro-descendant
- Located in United States or Canada
- Able to speak English
- Owns a smartphone
Exclusion Criteria:
- Any usage of psychotropic medication: not on a stable dosage 6+ weeks
- As needed (i.e., prn) benzodiazepine use
- Psychotic disorder (e.g., bipolar disorder, schizophrenia, schizoaffective disorder, psychosis)
- Cohabiting with a study participant
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: App-Delivered Mindfulness Training (MT)
The Unwinding Anxiety program is delivered via a smartphone-based platform, which includes a progression through 30+ daily modules of brief didactic and experience-based mindfulness training (videos and animations), app-triggered check-ins to encourage engagement, and user-initiated guided mindfulness exercises to help disrupt worry cycles in the moment.
|
Unwinding Anxiety is an app-delivered mindfulness training program which includes a progression through 30+ daily modules.
Each module's training is delivered via short video tutorials and animations (~10 min/day).
Each training builds on the previous one; modules are 'locked' so that they can only be viewed at a pace of 1/day (previous modules can be reviewed at any time).
A built-in self-assessment is taken after every seven modules to ensure key concepts are learned before moving on with automated suggestions on which modules to repeat based on the self-assessment results.
User-initiated guided practices range from short exercises (30 seconds) to manage anxiety the moment it arises to formal guided meditations (up to 15 minutes), and can be accessed at any time
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Focused interviews
Time Frame: Baseline
|
In-depth interviews will be conducted to collect participant feedback.
|
Baseline
|
|
Focused interviews
Time Frame: 2 months
|
In-depth interviews will be conducted to collect participant feedback.
|
2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in anxiety
Time Frame: Baseline, 2 months
|
Generalized Anxiety Disorder 7-item will be used to assess anxiety.
The GAD-7 is a 7-item questionnaire that uses a 4-point Likert scale where 0 is "Not at all" and 3 is "Nearly every day".
Scores can range from 0 to 21 and higher scores indicated a worse outcome.
|
Baseline, 2 months
|
|
Change in worry
Time Frame: Baseline, 2 months
|
Penn State Worry Questionnaire (PSWQ) will be used to assess worry.
The PSWQ is a 16-item questionnaire that uses a 5-point Likert scale where 1 is "Not at all typical of me" and 5 is "Very typical of me".
Scores can range from 16 to 80 and higher scores indicate a worse outcome
|
Baseline, 2 months
|
|
Change in non-reactivity
Time Frame: Baseline, 2 months
|
Non-reactivity subscale from the 15-item Five Facet Mindfulness Questionnaire (FFMQ) will be used to measure changes in emotional reactivity.
This subscale is based on responses to 3 questions measured on a 5-point Likert scale where 1 is "Never or rarely" and 5 is "Very often or always true".
Scores can range from 3 to 15 and higher scores indicate a better outcome.
|
Baseline, 2 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Judson A Brewer, Brown University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 6, 2022
Primary Completion (Actual)
February 5, 2024
Study Completion (Actual)
February 5, 2024
Study Registration Dates
First Submitted
November 4, 2022
First Submitted That Met QC Criteria
May 19, 2023
First Posted (Actual)
May 31, 2023
Study Record Updates
Last Update Posted (Actual)
March 15, 2024
Last Update Submitted That Met QC Criteria
March 13, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2112003165
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.